# McKESSON CORPORATION (MCK) FY2025 Q3 P&L / Income Statement

- Company: McKESSON CORPORATION (MCK)
- Period: 2024-10-01 to 2024-12-31
- Filing: Q3 FY2025 10-Q, filed 2025-02-06, accession number 0000927653-25-000014
- Page: https://plicit.ai/financials/mck/fy2025-q3-income-statement
- Chart image: https://plicit.ai/charts/mck-fy2025-q3-income-statement-sankey.png

## Chart details: Revenue by Business Segment

Income statement for 2024-10-01 through 2024-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 95,294,000,000 US dollars
- **Cost of sales**: 92,010,000,000 US dollars
- **Gross profit**: 3,284,000,000 US dollars
- **Total operating expenses**: 2,060,000,000 US dollars
- **Operating income**: 1,224,000,000 US dollars
- **Other income (expense), net (calculated)**: 2,000,000 US dollars
- **Income before income taxes**: 1,226,000,000 US dollars
- **Income tax benefit (expense)**: 298,000,000 US dollars
- **Net income**: 928,000,000 US dollars
- **U.S. Pharmaceutical**: 87,110,000,000 US dollars
- **Prescription Technology Solutions**: 1,371,000,000 US dollars
- **Medical-Surgical Solutions**: 2,949,000,000 US dollars
- **International**: 3,860,000,000 US dollars
- **Corporate**: 4,000,000 US dollars
- **Selling, distribution, general, and administrative expenses**: 2,028,000,000 US dollars
- **Claims and litigation charges, net**: 0 US dollars
- **Restructuring, impairment, and related charges, net**: 32,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to McKESSON CORPORATION: $879.00 M; to noncontrolling interests: $49.00 M.